Roivant Sciences Ltd.
GBPrice Chart
Financials
※ FY = Fiscal Year
Investment Metrics(as of 2026-06-18)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | $22.59B |
| Revenue | $8M |
| Net Income | $-300M |
| Total Assets | $5.73B |
| Net Assets | $4.53B |
| Employees | 750 |
| Value | |
| P/B | 4.99x |
| FCF Yield | -3.36% |
| Profitability | |
| ROE | -6.62% |
| ROA | -5.23% |
| Op. Margin | -15560.57% |
| Revenue Growth | -66.71% |
| Financial Health | |
| Debt Ratio | 9.62% |
| Total Debt | $107M |
| FCF | $-759M |
| Cash | $1.42B |
| Current Ratio | 18.37x |
| Performance | |
| 1Y Return | 174.56% |
| 1M Return | 11.34% |
| From 52W High | -4.21% |
| 1Y MDD | -12.84% |
| Trading | |
| Volume | 4,215,752 shares |
| Trading Value | $132M |
| Per Share | |
| EPS | $-1.16 |
| BPS | $6.13 |
Company Info
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising lipid nanoparticle (LNP) platform and ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.